Перейти к основному содержанию

SCIENTIFIC-PRACTICAL PEER-REVIEWED MONTHLY JOURNAL.
INSTITUTION OF MINISTRY OF PUBLIC HEALTH OF THE REPUBLIC OF BELARUS

VARIABILITY OF BIOMARKERS (AMYLOIDS Ab40, Ab42, TAU PROTEINS, PRP27-30) IN PATIENTS WITH ALZHEIMER’S DISEASE COMPARING WITH OTHER MENTAL AND NEURODEGENERATIVE DISORDERS

ßßObjective. To conduct comprehensive laboratory, clinic-neurological and neuroimaging examinations of patients with various cognitive disorders and to design biochips for detecting the neurodegeneration markers (amyloids Ab40, Ab42, protein PrP27—30) at various dementia states.

Materials and methods. One hundred and nine patients with various mental and neurodegenerative disorders were examined. To quantify the markers (Ab40, Ab42 and phosphoTau), the following ELISA test-systems were used: Ab40 Elisa Kit, Ab42 Elisa Kit, Human Tau [pT181] phosphoELISA Kit (USA). To indicate the amyloid Ab40, Ab42, and PrP27—30 protein more accurately biochips with activated sensory coatings of anti-Ab-amyloid and anti-prion antibodies were constructed. The pathological protein structures was identified using a Nanoscope IIId MultiMode microscope (USA) equipped with a
J-scanner. For the laboratory data statistical processing the independent groups was compared using the Kraskel — Wallis criterion (H, z). To compare the groups by the qualitative characteristics, conjugacy tables were used with the c2 criterion calculation. The value <0.05 was accepted as the critical level of significance (p-value) in the hypotheses testing.

Results. Patients with intellectual-mnestic disorders of various genesis were examined. Their neurological statuses were evaluated and the patients were differentiated into different groups. The quantitative levels of b-amyloids Ab40, Ab42, and tau protein were determined by ELISA test-systems in 109 patients’ blood plasma and in 10 persons’ cerebrospinal fluid (CSF). In the group of the AD patients, there was noticed a regular decrease in the blood plasma Ab40 (from 39.2±0.8 to 7.81±0.5 pg/ml), borderline values of the Ab42 titer (4.3±1.5 pg/ml) and increased levels of the tau protein (from 30.3±4.5 to 40.3±4.5 pg/ml). The parallel silicon biochips use made possible adsorption and identification of the b-amyloid Ab40, protein PrP27—30 by means of atomic force microscopy. The results obtained are important for assessing the degree of the degenerative-dystrophic changes in the central nervous system, for improving the methods of pathological process diagnosis and predicting the rate of development depending on the amyloidogenic proteins concentration and conformational structure.